Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 900 Shares of Stock

by · The Cerbat Gem

Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) Director Orbimed Advisors Llc sold 900 shares of the business’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $44.50, for a total value of $40,050.00. Following the completion of the sale, the director directly owned 3,595,986 shares in the company, valued at $160,021,377. This trade represents a 0.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Orbimed Advisors Llc also recently made the following trade(s):

  • On Friday, December 19th, Orbimed Advisors Llc sold 875 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.49, for a total transaction of $38,928.75.
  • On Thursday, December 18th, Orbimed Advisors Llc sold 100 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total transaction of $4,449.00.
  • On Wednesday, November 26th, Orbimed Advisors Llc sold 1,600 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total transaction of $71,184.00.
  • On Tuesday, November 25th, Orbimed Advisors Llc sold 11,890 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.60, for a total transaction of $530,294.00.
  • On Monday, November 24th, Orbimed Advisors Llc sold 94,583 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.54, for a total transaction of $4,212,726.82.

Sionna Therapeutics Trading Down 4.2%

Shares of NASDAQ:SION traded down $1.84 during trading on Friday, reaching $42.37. 1,954,673 shares of the stock traded hands, compared to its average volume of 270,007. The stock has a 50-day moving average of $38.54 and a two-hundred day moving average of $27.05. Sionna Therapeutics, Inc. has a 52-week low of $7.26 and a 52-week high of $45.00.

Sionna Therapeutics (NASDAQ:SION – Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.06.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. purchased a new stake in shares of Sionna Therapeutics in the 3rd quarter worth $30,000. BNP Paribas Financial Markets bought a new stake in Sionna Therapeutics during the second quarter valued at about $31,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Sionna Therapeutics in the second quarter worth about $45,000. China Universal Asset Management Co. Ltd. purchased a new stake in Sionna Therapeutics in the third quarter worth about $147,000. Finally, Virtus Investment Advisers LLC bought a new position in shares of Sionna Therapeutics in the second quarter worth about $96,000.

Analysts Set New Price Targets

A number of analysts have recently commented on SION shares. Royal Bank Of Canada reiterated an “underperform” rating and issued a $24.00 price target on shares of Sionna Therapeutics in a research note on Monday, December 1st. Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Jones Trading began coverage on Sionna Therapeutics in a report on Monday, September 8th. They set a “buy” rating and a $46.00 price target on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday. Finally, BTIG Research began coverage on Sionna Therapeutics in a research report on Wednesday, November 19th. They set a “buy” rating and a $50.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.33.

Get Our Latest Report on SION

About Sionna Therapeutics

(Get Free Report)

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

Featured Stories